Page 1

July 28 , 2021 Abeona THERAPEUTICS Abeona Therapeutics Reports Second Quarter Financial Results Second clinical trial site activated in EB - 101 pivotal Phase 3 VIITAL ™ M study Successful Type B meeting with U.S. FDA ; Transpher A study will serve as the pivotal study for ABO - 102 in MPS IIIA ; Alignment with FDA on primary study endpoint Focusing resources on completing EB - 101 and ABO - 102 pivotal , registration - enabling studies Conference call scheduled for Thursday , July 29 , 2021 at 8:30 a.m. ET Abeona NEW YORK and CLEVELAND , July 28 , 2021 ( GLOBE NEWSWIRE ) Therapeutics Inc. ( Nasdaq : ABEO ) , a fully - integrated leader in gene and cell therapy , today announced financial results for the second quarter 2021 and recent business progress . " The second quarter was a highly effective and productive quarter for Abeona , and we remain committed to delivering operational excellence and bringing our gene therapies to patients with no approved treatments , " said Michael Amoroso , Chief Executive Officer of Abeona . " As we continue to advance our clinical programs , we are delivering on meaningful milestones . We are focusing our resources on completing registration - enabling studies for patients with RDEB and MPS IIIA , and are preparing for the potential of two BLA filings . " Second Quarter and Recent Highlights Corporate Updates • Appointed Vishwas Seshadri , Ph.D. , M.B.A. , as Senior Vice President , Head of Research & Clinical Development . Dr. Seshadri joins Abeona from Celgene Corporation , now a subsidiary of Bristol - Myers Squibb Company , and brings substantial experience in the life sciences industry overseeing product development , regulatory submissions , and commercialization for novel therapies including personalized , autologous cell therapies . EB - 101 ( Autologous , Gene - Corrected Cell Therapy ) • Activated UMass Memorial Medical Center in Worcester , MA as the second clinical trial site in the pivotal Phase 3 VIITAL TM study of its investigational EB - 101 treatment for recessive dystrophic epidermolysis bullosa ( RDEB ) . • Presented updated Phase 1 / 2a clinical trial results at the Society for Pediatric Dermatology ( SPD ) 46th Annual Meeting , with EB - 101 treatment of large , chronic RDEB wounds continuing to show a considerable reduction in both wound burden and associated long - term pain for up to six years .